Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 7, 2013 - Issue
Submit an article Journal homepage
235
Views
22
CrossRef citations to date
0
Altmetric
Review

Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin

Annalisa Capuano1 Department of Experimental Medicine, Second University of Naples, Naples, Italy
,
Liberata Sportiello1 Department of Experimental Medicine, Second University of Naples, Naples, Italy
,
Maria Ida Maiorino2 Department of Medical, Surgical, Neurological, Metabolic Sciences, and Geriatrics, Second University of Naples, Naples, Italy
,
Francesco Rossi1 Department of Experimental Medicine, Second University of Naples, Naples, Italy
,
Dario Giugliano2 Department of Medical, Surgical, Neurological, Metabolic Sciences, and Geriatrics, Second University of Naples, Naples, ItalyCorrespondence[email protected]
&
Katherine Esposito3 Department of Clinical and Experimental Medicine and Surgery, Second University of Naples, Naples, Italy
Pages 989-1001 | Published online: 17 Sep 2013

Citations (22)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Tomas Lafarga & Maria Hayes. (2017) Bioactive protein hydrolysates in the functional food ingredient industry: Overcoming current challenges. Food Reviews International 33:3, pages 217-246.
Read now
Yutaka Seino & Daisuke Yabe. (2014) Alogliptin for the treatment of Type 2 diabetes. Expert Review of Endocrinology & Metabolism 9:6, pages 547-559.
Read now
Antonio Ceriello, Liberata Sportiello, Concetta Rafaniello & Francesco Rossi. (2014) DPP-4 inhibitors: pharmacological differences and their clinical implications. Expert Opinion on Drug Safety 13:sup1, pages 57-68.
Read now
Yutaka Seino & Daisuke Yabe. (2014) Alogliptin benzoate for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 15:6, pages 851-863.
Read now

Articles from other publishers (18)

Lily Park, Claudia Green, Sergey Arutyunyan, Gabriella Vasile, Christopher Buckley & Eduardo Weiss. (2022) Effects of canary seed on two patients with disseminated granuloma annulare. Dermatology Reports.
Crossref
Yongting Zhao, Xiaofang Zhang, Haihai Liang & Lihong Wang. (2022) Antidiabetic agents: Do they hit the right targets?. Frigid Zone Medicine 2:4, pages 225-243.
Crossref
Konstantin G. Gurevich, Yulia A. Sorokina, Alexander L. Urakov, Snezhana D. Sinyushkina, Maria I. Pryazhnikova, Alyona V. Gorinova, Lyubov V. Lovtsova & Olga V. Zanozina. (2022) Immunotropic effects of hypoglycemic agents on coronavirus infection: a view from the perspective of pharmacogenetics. Reviews on Clinical Pharmacology and Drug Therapy 20:3, pages 269-279.
Crossref
Prawej Ansari, Samara T. Choudhury, Veronique Seidel, Akib Bin Rahman, Md. Abdul Aziz, Anika E. Richi, Ayesha Rahman, Umme H. Jafrin, J. M. A. Hannan & Yasser H. A. Abdel-Wahab. (2022) Therapeutic Potential of Quercetin in the Management of Type-2 Diabetes Mellitus. Life 12:8, pages 1146.
Crossref
Marta Wolosowicz, Slawomir Prokopiuk & Tomasz W. Kaminski. (2022) Recent Advances in the Treatment of Insulin Resistance Targeting Molecular and Metabolic Pathways: Fighting a Losing Battle?. Medicina 58:4, pages 472.
Crossref
Bruno Dutra Arbo, Lucia Emanueli Schimith, Michele Goulart dos Santos & Mariana Appel Hort. (2022) Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation. European Journal of Pharmacology 919, pages 174800.
Crossref
Ana Maria Udrea, Gratiela Gradisteanu Pircalabioru, Anca Andreea Boboc, Catalina Mares, Andra Dinache, Maria Mernea & Speranta Avram. (2021) Advanced Bioinformatics Tools in the Pharmacokinetic Profiles of Natural and Synthetic Compounds with Anti-Diabetic Activity. Biomolecules 11:11, pages 1692.
Crossref
Chin-Ying Ray, Victor Chien-Chia Wu, Chun-Li Wang, Hui-Tzu Tu, Yu-Tung Huang, Chang-Fu Kuo & Shang-Hung Chang. (2021) Hypoglycemia Associated With Drug–Drug Interactions in Patients With Type 2 Diabetes Mellitus Using Dipeptidylpeptidase-4 Inhibitors. Frontiers in Pharmacology 12.
Crossref
Md Kamruzzaman, Michael Horowitz, Karen L. Jones & Chinmay S. Marathe. (2021) Gut-Based Strategies to Reduce Postprandial Glycaemia in Type 2 Diabetes. Frontiers in Endocrinology 12.
Crossref
Mariusz Dąbrowski. (2021) Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors. International Journal of Molecular Sciences 22:4, pages 1680.
Crossref
Sonia Rocha, Daniela Ribeiro, Eduarda Fernandes & Marisa Freitas. (2020) A Systematic Review on Anti-diabetic Properties of Chalcones. Current Medicinal Chemistry 27:14, pages 2257-2321.
Crossref
L. V. Kondratyeva. (2019) Early combination therapy for type 2 diabetes. Time for new decisions. Medical Council:12, pages 115-121.
Crossref
N. A. PetuninaA. L. Terekhova. (2019) Reliable choice in therapy of type 2 diabetes mellitus: focus on alogliptin. Medical Council:21, pages 138-145.
Crossref
N. A. Petunina, E. V. Goncharova & S. A. Potapova. (2017) CARDIOVASCULAR SAFETY OF GLIPTINS. FOCUS ON ALOGLIPTIN. Medical Council:3, pages 32-37.
Crossref
Carlo B. Giorda, Elisa Nada & Barbara Tartaglino. (2014) Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature. Endocrine 46:3, pages 406-419.
Crossref
Sandeep Chakraborty, Adela Rendón-Ramírez, Bjarni Ásgeirsson, Mouparna Dutta, Anindya S. Ghosh, Masataka Oda, Ravindra Venkatramani, Basuthkar J. Rao, Abhaya M. Dandekar & Félix M. Goñi. (2015) The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins. F1000Research 2, pages 286.
Crossref
Sandeep Chakraborty, Adela Rendón-Ramírez, Bjarni Ásgeirsson, Mouparna Dutta, Anindya S. Ghosh, Masataka Oda, Ravindra Venkatramani, Basuthkar J. Rao, Abhaya M. Dandekar & Félix M. Goñi. (2015) Dipeptidyl peptidase-IV inhibitors used in type-2 diabetes inhibit a phospholipase C: a case of promiscuous scaffolds in proteins. F1000Research 2, pages 286.
Crossref
Sandeep Chakraborty, Adela Rendón-Ramírez, Bjarni Ásgeirsson, Mouparna Dutta, Anindya S. Ghosh, Masataka Oda, Ravindra Venkatramani, Basuthkar J. Rao, Abhaya M. Dandekar & Félix M. Goñi. (2013) Dipeptidyl peptidase-IV inhibitors used in type-2 diabetes inhibit a phospholipase C: a case of promiscuous scaffolds in proteins. F1000Research 2, pages 286.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.